SIRPA and neoplasm: Inspired by the facts that disrupting the CD47-SIRPα signaling axis with CV1 enhances the anti-tumor efficacy of CAR-T cells25, and that CD47 blockades can improve the activation and recruitment of NK cells47, we further wonder whether CV1 could augment the effectiveness of CDH17-CAR-NK92 cells (Fig. 6A).